• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali

Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali

by Annie De Groot | Mar 1, 2019

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

by Sarah Moniz | Apr 10, 2018

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

by Adam | Oct 22, 2016

Development of Scoring Functions for Antibody Sequence Assessment and Optimization. Boehringer Ingelheim Pharma PLoS One. 2013; 8(10) [Use of ISPRI tool to develop Humanized antibody concept].
Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods

Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods

by Adam | Oct 22, 2016

PlosOne. 2014 Apr 16. Full Text

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?
  • Tregs as Medicine: Tolerance and InTolerance Seminar
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline